Amarin Corp Plc (AMRN)

[Whalatane]

Hi Bio

Most of us agree that Vascepa will reduce CV risk in the Reduce It population . The question is when will that become apparent enough to stop the trial .

JL expects 40% benefit and trial stopped late 2015 ..if I'm reading his posts correctly.
So if AMRN conserves cash its no problem coasting to then

HDGabor and others ( myself included ) think Interim analysis early mid 2016 is a more likely stopping point.
So how do we make it to then ?

If Amarin were to run a TV ad ..it would be expensive and inefficient and they would probably only mention that it was FDA approved for very high TG's .

Amarin should have very sophisticated sales analysis data .
IE ..which specialities ( Cardiologists ) in which Hospitals or private practice prescribe the most ....is there a common thread .
Do they sell more in Florida ..higher retired population etc

Do areas of high Govt employees prescribe more because of the generous health care plan these employees or retires receive ...etc

This is what was called the "rifle " approach to marketing ...targeting high probability areas vs the "shotgun " approach of a TV ad.

If you really want to waste some $ ...buy a super bowl ad
JMO
Kiwi